06 Mar 2018 Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors
03 Mar 2018 Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis
02 Mar 2018 TCR-Based Antibodies, Fusion Proteins and Cell-Penetrating Biologics to Tap the Intracellular Target Pool
02 Mar 2018 FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
28 Feb 2018 Chugai's HEMLIBRA® Approved by European Commission in Hemophilia A with Inhibitors
28 Feb 2018 BioAtla Announces First Patient Treated In Phase1/2 BA3011-001 Clinical Trial For CAB-AXL-ADC Therapeutic
26 Feb 2018 Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer
26 Feb 2018 New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes
25 Feb 2018 Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®
25 Feb 2018 FDA Accepts Shire's Biologics License Application (BLA) and Grants Priority Review for Lanadelumab for the Prevention of Attacks in Hereditary Angioedema (HAE) Patients
25 Feb 2018 Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children
25 Feb 2018 Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
22 Feb 2018 MabSpace Biosciences Announces FDA Approval of IND for MSB2311, a Second Generation PD-L1 Antibody With pH Dependent Antigen Binding and Recycling Property
22 Feb 2018 Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer
22 Feb 2018 Xencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal Tumors
22 Feb 2018 Europe Approves JHL Biotech's Clinical Trial Application for Bevacizumab Biosimilar to Affordably Treat Colorectal, Lung, and Ovarian Cancers
20 Feb 2018 Russian infliximab biosimilar has been proved equivalent to Remicade® in international clinical trials
18 Feb 2018 CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study
18 Feb 2018 Glenmark Pharmaceuticals Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
18 Feb 2018 Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease Patients in Comparative Effectiveness Real-World Data Analysis
18 Feb 2018 AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting
18 Feb 2018 US FDA approves Imfinzi for unresectable Stage III non-small cell lung cancer
17 Feb 2018 UCB Advances Psoriasis Pipeline with Positive Data at American Academy of Dermatology Annual Meeting (AAD 2018)
17 Feb 2018 MorphoSys and Galapagos Present Results from a Phase 1 Study with MOR106 in Atopic Dermatitis as Late-Breaking Abstract at the American Academy of Dermatology (AAD) Meeting in San Diego
16 Feb 2018 Omeros Reports Significant Improvement in Overall Survival Data in OMS721-Treated Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing